Using telemedicine to combat drug addiction comes with challenges

Rural areas hit hard by the rise in opioid addiction often lack the needed treatment expertise, but health professionals may have a solution: video chat.

As reported by Kaiser Health News, $1.4 million in federal grants are funding pilot projects in Virginia, Tennessee and Kentucky that use telemedicine to connect patients with physicians who know how to treat addiction.

“This is an obvious potential direction to move in,” said Colleen Barry, a professor of health policy at Johns Hopkins University and co-director of its Center for Mental Health and Addiction Policy Research. “There are some real opportunities—and some pretty significant challenges.”

That’s especially true at the southwest Virginia clinic of family physician Robert Devereaux, MD. While telemedicine can link patients to psychiatrists, prescribing medication to wean addicts off opioids require in-person visits—and Devereaux already sees 25 to 30 patients a day.

There's also the concerns about payment. Federal grants can cover the technology cost but not the actual treatment, and patients may be left to pay out of pocket for the consultations and the medication.

For more on how physicians and regulators are trying to overcome these obstacles, click on the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.